首页> 美国卫生研究院文献>International Journal of Molecular Sciences >HTK-N: Modified Histidine-Tryptophan-Ketoglutarate Solution—A Promising New Tool in Solid Organ Preservation
【2h】

HTK-N: Modified Histidine-Tryptophan-Ketoglutarate Solution—A Promising New Tool in Solid Organ Preservation

机译:HTK-N:修饰的组氨酸 - 色氨酸 - 酮戊酸酯解决方案 - 固体器官保存中有希望的新工具

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

To ameliorate ischemia-induced graft injury, optimal organ preservation remains a critical hallmark event in solid organ transplantation. Although numerous preservation solutions are in use, they still have functional limitations. Here, we present a concise review of a modified Histidine-Tryptophan-Ketoglutarate (HTK) solution, named HTK-N. Its composition differs from standard HTK solution, carrying larger antioxidative capacity and providing inherent toxicity as well as improved tolerance to cold aiming to attenuate cold storage injury in organ transplantation. The amino acids glycine, alanine and arginine were supplemented, N-acetyl-histidine partially replaced histidine, and aspartate and lactobionate substituted chloride. Several in vitro studies confirmed the superiority of HTK-N in comparison to HTK, being tested in vivo in animal models for liver, kidney, pancreas, small bowel, heart and lung transplantation to adjust ingredients for required conditions, as well as to determine its innocuousness, applicability and potential advantages. HTK-N solution has proven to be advantageous especially in the preservation of liver and heart grafts in vivo and in vitro. Thus, ongoing clinical trials and further studies in large animal models and consequently in humans are inevitable to show its ability minimizing ischemia-induced graft injury in the sequel of organ transplantation.
机译:为了改善缺血诱导的接枝损伤,最佳器官保存仍然是固体器官移植的关键标志事件。虽然使用了许多保存解决方案,但它们仍然具有功能限制。在这里,我们展示了修饰的组氨酸 - 色氨酸 - ketoglutarate(HTK)解决方案的简明审查,名为HTK-N.其组成与标准HTK溶液不同,携带较大的抗氧化能力并提供固有的毒性,以及改善对冷的耐受性,以衰减器官移植中的冷储物损伤。补充氨基酸甘氨酸,丙氨酸和精氨酸,n-乙酰基 - 组氨酸部分替代的组氨酸,并加热酸盐和乳炔属取代的氯化物。几种体外研究证实与HTK相比,HTK-N的优越性与HTK进行了比较,在肝脏,肾脏,胰腺,小肠,心脏和肺移植的动物模型中进行测试,以调整所需条件的成分,以及确定其无害,适用性和潜在的优势。 HTK-N溶液已被证明是有利的,特别是在体内和体外保存肝脏和心脏移植物。因此,正在进行的临床试验和大型动物模型的进一步研究,因此在人类中是不可避免的,以表明其能力最小化缺血诱导的器官移植续集中的接枝损伤。

著录项

相似文献

  • 外文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号